Do CYP2D6 genotypes affect oxycodone dose, pharmacokinetics, pain, and adverse effects in cancer?
There was no observed benefit in <i>CYP2D6</i> genotyping in oxycodone response, however monitoring noroxycodone and oxymorphone concentrations warrant further examination.
Authors
- Pål Klepstad (ORCID: https://orcid.org/0000-0003-2804-8447)
- Jennifer A. M. Philip (ORCID: https://orcid.org/0000-0002-3312-0645)
- Sara Vogrin (ORCID: https://orcid.org/0000-0002-1597-9421)
- Brian Le (ORCID: https://orcid.org/0000-0002-0830-4864)
- Justin P. Rubio (ORCID: https://orcid.org/0000-0003-3750-917X)
- Aaron Wong (ORCID: https://orcid.org/0000-0002-6507-1219)
- Andrew A. Somogyi (ORCID: https://orcid.org/0000-0003-4779-0380)
Institutions
- The Royal Melbourne Hospital (AU)
- The University of Melbourne (AU)
- Florey Institute of Neuroscience and Mental Health (AU)
- Peter MacCallum Cancer Centre (AU)
- St Vincent's Hospital Melbourne (AU)
- Eastern Health (AU)
- St Olav's University Hospital (NO)
- The University of Adelaide (AU)
Publication Details
- Journal
- Pharmacogenomics
- Published
- 2024-10-12
- DOI
- https://doi.org/10.1080/14622416.2024.2430161
- Primary Topic
- Pain Management and Opioid Use
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bethlehem Griffiths Research Foundation
- Medical Research Council
- National Health and Medical Research Council